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PRELIMINARY AND SHORT REPORTS
ATABRINE IN THE TREATMENT OF DISCOID LUPUS ERYTHEMATOSLTS*
JEAN A. CRAMER, M.D. AND GEORGE M. LEWIS, M.D.
No remedy advocated for the treatment of chronic discoid lupus erythematosus has
proved invariably helpful or unquestionably safe. Such drugs as gold, bismuth, liver ex-
tract, sodium para-amino beuzoate, sulfonamides, penicillin and quinine are all utilized
and not infrequently in the same patient. More recently, reports have appeared on the use
of calcium pantothenate, both alone and in combination with Vitamin E (1, 2). Vitamin
E both by the oral and the parenteral routes has been employed (3, 4). The adrenocortico-
steroids have been tried with only transient improvement (5, 6, 7).
An article by Page (8), on the treatment of eighteen cases of lupus erythematosus with
Mepacrine® (Atabrine) first drew our attention to this form of therapy. There were seven-
teen cases of chronic discoid lupus erythematosus, and one case of the acute disseminated
form. Only one patient failed to respond, and fourteen showed good to excellent improve-
ment, several demonstrating complete disappearance of their lesions. Rook (9) also found
this drug useful. No serious reactions were encountered. Bispham (10) reported on 46,681
patients who received Atabrine® for the treatment or prophylaxis of malaria; only 38 cases
of toxic reactions were found. Nisbet (11) and others observed eruptions classified as patchy
eczematoid, hypertrophic lichenoid (lichen-planus like) and generalized exfoliative der-
matitis as very occasional complications, especially if the drug is ingested as long as three
to six months. Agress (12) found the incidence of toxic reactions to be less than one twentieth
of 1 per cent in his group of 3000 patients. Deaths due to aplastic anemia (13) and hepatitis
(14) have been recorded.
METH0n
Because of the reputed low incidence (10, 12) of serious side effects, it was decided to
follow the maximum dosage schedule suggested by Page (8), in a pilot group. Studies to
rule out disseminated lupus erythematosus and other disorders included a complete blood
count, erythrocyte sedimentation rate, urinalysis, blood protein determination with al-
bumin-globulin ratio, and a roentgeoogram of the chest. Six patients with typical long-
standing chronic discoid lupus erythematosus, who had previously received many other
types of standard therapy, were selected for experimental treatment. The patients were in-
structed to take 0.1 gm. of atabrine dihydrochloride® (Winthrop-Stearns) daily for one
week, and to then increase the dosage to 0.1 gm. three times a day. Each dose was taken
one-half hour after eating, with an alkalinizing agent (either orange juice or sodium bi-
carbonate). The drug was given for periods ranging from eight to sixteen weeks.
RESULTS
The responses were favorable and promptly achieved in five of the six patients (see
Table 1). A yellow discoloration of the skin, similar to icterus, occurred in all cases. The
patients found the jaundiced tinge of their skin only a cosmetic nuisance. The most pro-
nounced improvement coincided fairly well with the degree of yellow staining of the skin.
Maximum pigmentation was seen in the third and fourth weeks of therapy. B. C. (case 5)
is a good example of the results obtained. Within four weeks of treatment with Atabrine®,
all of the more recent lesions had completely cleared, and the erythema and induration of
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the older lesions had disappeared. With the completion of two months of treatment, the
only residuum was the atrophic scarring present before giving the drug. A young woman
(case 3) with a chronic scalp lesion exhibiting much scarring, can only be regarded as a fair
result, although activity in the lesion was halted by the therapy. Four of the six patients
are still on maintainance therapy (i.e. one or two tablets daily). The erythrocyte sedimenta-
tion rate was significantly elevated in three of the six patients. This test may be used as a
guide to the activity of the disease process (15). In two patients (cases 4 and 5) the erythro-
cyte sedimentation rate fell after two months of treatment. Leukocyte count aod uriaaly-
TABLE 1
Resolts of Therapy with Atabrine ® in Six Gases of Discoid Lopos Erythetnatosos
ERYTOROCYTE
SEDIMENTATION DURiO
BIOPSY DU- RATE* TIONPATIENT AGE SEX SITES - RA- PREVIOUS TSSEESPY OP RESULTRESLLT TION - TSIER-
Bef SCI After Am
years weeks




B.G. 43 F Gheeles, L.E. S Bismuth, gold, solid 36 42 11 Excel-
fore- GO2, Vitamins B lent
head, and E, cortisone,
upper crude liver cx-
lip tract, calcium
paotothenate
T.D. 34 F Scalp None 10 Liver extract, his- 26 10 Fair
muth, solid GO2
G.G. 42 F Gheeks, L.E. 12 Bismuth, gold, liver 42 S S Excel-
nose extract lent
B.G. 61 M (leeks, L.E. 12 Bismuth, gold, Vi- 43 25 16 Excel-
cars, tamins B and E, lent
back, liver extract, x-
arms rays to back
AG. 63 M Face, Equiv- 1 X-rays, local oint- 16 Excel-
ears, ocal ments, bismuth, lent
scalp Vitamin E
* Normal values, Wintrohe Erythrocyte Sedimentation Rate: Male 0—9 mm. per hour
Female, 0—20 mm. per
hour
sis were repeated during the course of therapy, but no abnormal finding was discovered.
The only complication from the administration of Atabrinc® noted was the discoloration
of the skin. We cannot report on recurrence, as only two patients are not taking the medica-
tion at the present time.
cONcLUsSONs
In view of the rapidity of improvement seen in six patients with lupus crythematosus
treated with Atabrine®, it can be concluded that this drug offers anothcr therapeutic tool
which may be useful in selected cases. The simplicity of administration and the low mci-
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dence of complicatioos (10, 11) are additional factors io favor of this type of treatment.
The slight possibility of a serious dermal reaction and the remote chance of a fatal outcome
(12, 13) must be kept in mind to counterbalance any heedless enthusiasm that may be en-
gendered from a consideration of the good temporary results which are here reported.
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